drugset / Trial / NCT04943848
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
Phase 1
Recruiting
36 enrolled
Ann & Robert H Lurie Children's Hospital of Chicago
Children's Hospital of Orange County · collabDana-Farber Cancer Institute · collabUniversity of Calgary · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting neo-epitopes found in the majority of DIPG and DMG tumors. Newly diagnosed patients with DIPG and DMG who have completed radiation six to ten weeks prior to enrollment are eligible.
Timeline
- Start
- 2022-01-10
- Primary completion
- 2026-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Balstilimab | Monoclonal antibody | — | — |
| Subject | Zalifrelimab | Monoclonal antibody | — | — |
| Subject | rHSC-DIPGVax | Vaccine | — | — |